文献速递血栓与止血

老年急性静脉血栓栓塞症患者出血事件的发生率及临床影响

Incidence and clinical impact of bleeding events in older patients with acute venous thromboembolism.
PubMed 文献 · Blood Adv · 2023-01-01

该前瞻性多中心队列纳入981例年龄≥65岁的急性静脉血栓栓塞症(VTE)患者,其中88%使用维生素K拮抗剂抗凝。随访至36个月内发生100例大出血(MB)和125例临床相关非大出血(CRNMB),MB发生率为8.5例/100患者年(95%CI 7.0-10.4),CRNMB为13.4例/100患者年(95%CI 11.4-15.7)。活动性癌症和低体力活动与MB相关,高跌倒风险与CRNMB相关。

要点

  • 老年VTE抗凝患者MB发生率为8.5例/100患者年,CRNMB为13.4例/100患者年。
  • MB中79%需住院、18%需手术干预、19%需永久停用抗凝,15%为颅内出血、6%致命。
  • 活动性癌症(SHR 1.81)和低体力活动(SHR 1.88)与MB相关,高跌倒风险(SHR 2.04)与CRNMB相关。

核心结论

  • 老年VTE抗凝患者MB和CRNMB发生率高,出血事件造成较大疾病负担,医生应仔细权衡老年VTE人群延长抗凝的风险与获益。

研究设计与样本

  • 前瞻性多中心队列研究,纳入981例年龄≥65岁的急性VTE患者,其中88%使用维生素K拮抗剂抗凝。

主要发现

  • 随访至36个月内发生100例MB和125例CRNMB事件。
  • MB发生率为8.5例/100患者年(95%CI 7.0-10.4),CRNMB为13.4例/100患者年(95%CI 11.4-15.7)。
  • MB患者中79%需住院、18%需手术干预、19%需永久停用抗凝,15%为颅内出血、6%致命。
  • 校正后活动性癌症与MB相关(SHR 1.81,95%CI 1.12-2.93),低体力活动与MB相关(SHR 1.88,95%CI 1.19-2.98),高跌倒风险与CRNMB相关(SHR 2.04,95%CI 1.39-3.00)。

临床怎么用

  • 医生应仔细权衡老年VTE人群延长抗凝的风险与获益。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Older patients anticoagulated for venous thromboembolism (VTE) have an increased risk of bleeding compared with younger patients. Little is known about the clinical impact of anticoagulation-related bleeding in this growing patient group. To prospectively assess the incidence, clinical impact, and predictors of bleeding in older patients anticoagulated for VTE, we analyzed 981 patients aged ≥65 years with acute VTE in a prospective multicenter cohort. Eight-eight percent were anticoagulated with vitamin K antagonists. Outcomes were the occurrence of major bleeding (MB) or clinically relevant nonmajor bleeding (CRNMB) event during the initial anticoagulation period up to 36 months. We described the incidence and clinical impact of bleeding and examined the association between risk factors and time to a first bleeding using competing risk regression; 100 MB and 125 CRNMB events occurred during follow-up. The incidence of MB and CRNMB was 8.5 (95% confidence interval [CI], 7.0-10.4) and 13.4 events (95% CI, 11.4-15.7) per 100 patient-years, respectively. In patients with MB, 79% required hospitalization, 18% required surgical intervention, and 19% required permanent discontinuation of anticoagulation; 15% of MB were intracranial and 6% were fatal. After adjustment, active cancer (subhazard ratio [SHR], 1.81; 95% CI, 1.12-2.93) and low physical activity (SHR, 1.88; 95% CI, 1.19-2.98) were associated with MB and high risk of falls with CRNMB (SHR, 2.04; 95% CI, 1.39-3.00). Older patients anticoagulated for VTE had a high incidence of MB and CRNMB, and these bleeding episodes caused a great burden of disease. Physicians should carefully weigh the risks/benefits of extended anticoagulation in the older population with VTE.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ferrazzini E, Méan M, Stalder O, et al. Incidence and clinical impact of bleeding events in older patients with acute venous thromboembolism. Blood Adv. 2023. PMID: 35381071. doi:10.1182/bloodadvances.2022007263

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。